Personality traits and early discontinuation from clinical trials in anxious patients.
Patients who discontinue early from clinical trials frequently give ambiguous or no reasons for leaving the study. Using Cloniger's Tridimensional Personality Questionnaire, we examined the potential role of personality traits in early discontinuation in patients with panic disorder and generalized anxiety disorder. Early dropouts and completers were comparable at baseline on demographic and clinical variables but differed significantly on the Tridimensional Personality Questionnaire. For panic disorder and generalized anxiety disorder patients combined, early dropouts scored higher on total novelty seeking, as well as on the novelty-seeking traits of both disorderliness/dislike of regimentation and impulsiveness. There was no significant interaction between dropout status and diagnosis for this finding, indicating it applied equally to both groups. This study suggests that personality traits involving novelty seeking may contribute to early discontinuation from clinical trials, independent of side effects, lack of efficacy, or at baseline, significantly worse symptoms of anxiety.
Wingerson
D
D
Center For Anxiety and Depression, University of Washington School of Medicine, Seattle.
Sullivan
M
M
Dager
S
S
Flick
S
S
Dunner
D
D
Roy-Byrne
P
P
D000328:Adult; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000523:psychology; D001569:Benzodiazepines; D002986:Clinical Trials as Topic; D003674:Defense Mechanisms; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016584:Panic Disorder / Q000188:drug therapy* / Q000523:psychology; D010349:Patient Compliance / Q000523:psychology; D010352:Patient Dropouts / Q000523:psychology*; D010555:Personality Inventory; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use
D014151:Anti-Anxiety Agents; D001569:Benzodiazepines; D017367:Selective Serotonin Reuptake Inhibitors